Patients treated with ocrelizumab or fingolimod had significant lower anti-RBD IgG levels compared to patients treated with cladribine (P < 0.0001, P = 0.0024, respectively) or IFN-β (P < 0.0001, P = 0.0004, respectively; Figure 1D, Table 2) and compared to “no MS” subjects (P < 0.0001, P = 0.0071, respectively; Table 2). Here, IFNB1 is linked to myeloid sarcoma.